News and Announcements
Analytica Limited (ASX: ALT) completes Renouncable Entitlement Offer with over $1 million raised
- Published June 08, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Analytica Limited has announced the successful completion of the renounceable entitlement offer with $1.045m raised.
- The Entitlement offered one new share for every eight shares held on the 21 of September 2017.
- The entitlement offer aimed to raise funds to continue the development of their PeriCoach system.
Analytica Limited has announced the successful completion of their entitlement offer that was announced in September 2017. The renounceable entitlement offer resulted in $1.045m raised through options exercised before the expiration of two options provided. The Entitlement offered one new share for every eight shares held on the 21 of September 2017. Option 1 stated that shares subscribed to are exercisable at $0.005 on or before 31 January 2018, or Option 2 exercisable at $0.005 on or before 31 May 2018. Following Option 1, a total of $919k worth of exercised options was raised and Option 2 raised a total of $1.045k through the exercised options. A further $487k was raised from private placements with unlisted options exercisable at the same $0.005.
The entitlement offer aimed to raise funds to continue the development of their PeriCoach system. PeriCoach is a medical system that allows remote physicians to monitor a woman’s Stress Urinary Incontinence condition. The support of shareholders in pursuing this goal of development was appreciated by Analytica Limited, and the shares will be allocated on 13 June 2018.
About Analytica Limited (ASX: ALT)
Analytica Limited (ASX: ALT) is an Australian medical device manufacturing and commercialisation company.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
